# Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

> **NCT03764475** · PHASE2 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 332 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Roflumilast

## Key facts

- **NCT ID:** NCT03764475
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-18
- **Primary completion:** 2020-10-08
- **Final completion:** 2020-10-08
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03764475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03764475, "Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03764475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*